Cannabis Market to Skyrocket to USD 174.70 billion by 2033, Registering a 24% CAGR

The global cannabis market is set for unprecedented growth, with its size valued at USD  20.33 billion in 2024 . Driven by key market catalysts, the market is projected to surge, reaching USD 174.70 billion by 2033 at an impressive compound annual growth rate (CAGR) of 24% during the forecast period of 2023–2031.

Catalysts Driving Cannabis Market Expansion                                                                                                                    Download Free Sample

The expansion of the cannabis market is powered by increasing legalization of cannabis for both medical and recreational use across several regions. Technological advancements in product development, such as edibles, concentrates, and capsules, have attracted a diverse customer base. Additionally, growing awareness regarding cannabis' therapeutic benefits in treating chronic diseases, pain management, and mental health conditions further fuels demand.

Market Segmentation Highlights

The cannabis market is segmented into product type, application, and compound type:

• By Product Type:

  1. Capsules
  2. Concentrates
  3. Edibles
  4. Other Product Types

• By Application:

  1. Medical
  2. Recreational

• By Compound Type:

  1. Tetrahydrocannabinol (THC)
  2. Cannabidiol (CBD)
  3. Balanced THC and CBD

• To purchase the complete report, click here: Buy Now

Each of these segments is witnessing steady growth, with the medical cannabis segment expected to dominate due to its widespread application in chronic illness treatments. The recreational segment is anticipated to gain momentum, particularly in regions where cannabis legalization for adult use is growing.

Top Performing Companies Leading the Market

Several key players are driving innovation and competition in the cannabis market, ensuring its robust development:

1. Tilray
2. Canopy Growth Corp
3. GW Pharmaceuticals PLC
4. Aurora Cannabis Inc.
5. Aphira Inc.
6. MedReLeaf Corp
7. CV Sciences Inc.
8. Delta 9 Cannabis
9. CanniMed Therapeutics Inc.
10. Vivo Cannabis
11. Good Leaf
12. Halo Labs

These companies are focusing on expanding their product portfolios, conducting extensive R&D, and entering strategic partnerships to strengthen their market presence and meet increasing global demand.

Emerging Prospects in the Cannabis Market

The cannabis market is witnessing several promising opportunities, including:

• Increased Investment in Research: Pharmaceutical and biotech companies are focusing on clinical research to unlock new therapeutic applications of cannabis, including treatment for neurological disorders, epilepsy, and cancer-related symptoms.
• Product Diversification: Beyond traditional methods of consumption, innovative formats like oils, edibles, and capsules have significantly broadened the consumer demographic.
• Global Legalization Trends: Many countries are actively considering or implementing policies to legalize cannabis for medical and recreational purposes, which opens new revenue streams for businesses.

Industry Movements and Regional Analysis

The North American market remains dominant, with Canada and several U.S. states leading cannabis legalization efforts. Europe is rapidly catching up, particularly in Germany, Italy, and the Netherlands, where medical cannabis use is expanding. Meanwhile, the Asia-Pacific region presents untapped potential as nations begin discussions around legal and regulated cannabis markets.

Strategic initiatives such as mergers, acquisitions, and partnerships are key movements in the industry, allowing businesses to enter new geographic markets and strengthen their foothold.

Insights and Company Details

This report is provided by Straits Research, a leading provider of business intelligence, specializing in research, analytics, and advisory services. Straits Research delivers in-depth insights to help organizations make data-driven decisions and remain competitive in dynamic markets.

Contact Us:
Straits Research

• Email: sales@straitsresearch.com
• Address: 825 3rd Avenue, New York, NY, USA, 10022
• Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)